Bo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bo Xu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Chunying Yang
Department of Radiation Oncology, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA, Department of Oncology, Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, USA
2 shared publicationsHaibo Wang
Department of Radiation Oncology, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA
2 shared publicationsRebecca J. Boohaker
Southern Research Institute
2 shared publicationsWei Zhang
Department of Medicinal Chemistry, Southern Research Institute, Birmingham, AL 35205, USA and
2 shared publicationsXiaojing Guo
Department of Radiation Oncology, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA
2 shared publicationsChunling Jiang
Nanchang University Graduate School, Nanchang 330047, China
1 shared publication
Latest Publications
- 21 October 2016
- Published by Springer Nature
- p. 183-193
The Role of MicroRNAs in Modulating Tissue Response to Radiation
- 21 October 2016
- Published by Springer Nature
- p. 183-193
The Role of MicroRNAs in Modulating Tissue Response to Radiation
- Open Access
- 6 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (33) , 34649-34657
A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas
A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas
- 6 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (33) , 34649-34657
Open AccessA radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas
A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas
- Open Access
- 11 April 2014
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 35 (9) , 2007-2013
ATM-mediated Mad1 Serine 214 phosphorylation regulates Mad1 dimerization and the spindle assembly checkpoint
The spindle assembly checkpoint (SAC), which blocks anaphase onset until all chromosomes have bi-oriented, is one of the key self-monitoring systems of the eukaryotic cell cycle for genome stability. The mitotic arrest-deficient protein 1 (Mad1), a critical component of the SAC, is hyperphosphorylated in mitosis. However, the kinases responsible for Mad1 phosphorylation and its functional significance are not fully understood. Here we report that Mad1 is phosphorylated on Serine 214 by the Ataxia-Telangiectasia Mutated (ATM) kinase, a critical DNA damage response protein also activated in mitosis and required for the SAC. We demonstrate that Mad1 Serine 214 phosphorylation promotes the formation of homodimerization of Mad1 and its heterodimerization with Mad2. Further we show that Mad1 Serine 214 phosphorylation contribute to activation of the SAC and the maintenance of chromosomal stability. Together, these findings reveal an important role of ATM-mediated Mad1 Serine 214 phosphorylation in mitosis.
- 11 April 2014
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 35 (9) , 2007-2013
Open AccessATM-mediated Mad1 Serine 214 phosphorylation regulates Mad1 dimerization and the spindle assembly checkpoint
The spindle assembly checkpoint (SAC), which blocks anaphase onset until all chromosomes have bi-oriented, is one of the key self-monitoring systems of the eukaryotic cell cycle for genome stability. The mitotic arrest-deficient protein 1 (Mad1), a critical component of the SAC, is hyperphosphorylated in mitosis. However, the kinases responsible for Mad1 phosphorylation and its functional significance are not fully understood. Here we report that Mad1 is phosphorylated on Serine 214 by the Ataxia-Telangiectasia Mutated (ATM) kinase, a critical DNA damage response protein also activated in mitosis and required for the SAC. We demonstrate that Mad1 Serine 214 phosphorylation promotes the formation of homodimerization of Mad1 and its heterodimerization with Mad2. Further we show that Mad1 Serine 214 phosphorylation contribute to activation of the SAC and the maintenance of chromosomal stability. Together, these findings reveal an important role of ATM-mediated Mad1 Serine 214 phosphorylation in mitosis.
- Open Access
- 22 January 2014
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 35 (8) , 1691-1697
Speckle-type POZ protein, SPOP, is involved in the DNA damage response
Speckle-type POZ protein (SPOP) is an adaptor of the cullin 3-based ubiquitin ligase responsible for the degradation of oncoproteins frequently overexpressed in many tumor cells. Altered expression and somatic mutations of SPOP have been observed in various tumor types with chromosomal aberrations, indicating a role of SPOP in maintaining genome stability, although a detailed mechanism remains unclear. Here, we show that SPOP is a component of the DNA damage response (DDR). SPOP is recruited to DNA double-strand break sites and it forms nuclear foci after DNA damage. SPOP foci colocalize with γ-H2AX foci and are predominantly dependent on the activity of the ataxia-telangiectasia mutated (ATM) kinase. Furthermore, SPOP interacts with ATM in response to DNA damage. Finally, we demonstrate that knocking down of SPOP resulted in an impaired DDR and a hypersensitivity to ionizing irradiation. Together, we highlight a critical role of SPOP in the DDR.
- 22 January 2014
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 35 (8) , 1691-1697
Open AccessSpeckle-type POZ protein, SPOP, is involved in the DNA damage response
Speckle-type POZ protein (SPOP) is an adaptor of the cullin 3-based ubiquitin ligase responsible for the degradation of oncoproteins frequently overexpressed in many tumor cells. Altered expression and somatic mutations of SPOP have been observed in various tumor types with chromosomal aberrations, indicating a role of SPOP in maintaining genome stability, although a detailed mechanism remains unclear. Here, we show that SPOP is a component of the DNA damage response (DDR). SPOP is recruited to DNA double-strand break sites and it forms nuclear foci after DNA damage. SPOP foci colocalize with γ-H2AX foci and are predominantly dependent on the activity of the ataxia-telangiectasia mutated (ATM) kinase. Furthermore, SPOP interacts with ATM in response to DNA damage. Finally, we demonstrate that knocking down of SPOP resulted in an impaired DDR and a hypersensitivity to ionizing irradiation. Together, we highlight a critical role of SPOP in the DDR.
- Open Access
- 1 January 2014
- Published by Elsevier in Biomedical Journal
- Vol. 37 (1) , 3-9
The versatile functions of ATM kinase
- 1 January 2014
- Published by Elsevier in Biomedical Journal
- Vol. 37 (1) , 3-9
Open AccessThe versatile functions of ATM kinase
- Open Access
- 26 September 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 223
New insights into the synergism of nucleoside analogs with radiotherapy
Nucleoside analogs have been frequently used in combination with radiotherapy in the clinical setting, as it has long been understood that inhibition of DNA repair pathways is an important means by which many nucleoside analogs synergize. Recent advances in our understanding of the structure and function of deoxycytidine kinase (dCK), a critical enzyme required for the anti-tumor activity for many nucleoside analogs, have clarified the mechanistic role this kinase plays in chemo- and radio-sensitization. A heretofore unrecognized role of dCK in the DNA damage response and cell cycle machinery has helped explain the synergistic effect of these agents with radiotherapy. Since most currently employed nucleoside analogs are primarily activated by dCK, these findings lend fresh impetus to efforts focused on profiling and modulating dCK expression and activity in tumors. In this review we will briefly review the pharmacology and biochemistry of the major nucleoside analogs in clinical use that are activated by dCK. This will be followed by discussions of recent advances in our understanding of dCK activation via post-translational modifications in response to radiation and current strategies aimed at enhancing this activity in cancer cells.
- 26 September 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 223
Open AccessNew insights into the synergism of nucleoside analogs with radiotherapy
Nucleoside analogs have been frequently used in combination with radiotherapy in the clinical setting, as it has long been understood that inhibition of DNA repair pathways is an important means by which many nucleoside analogs synergize. Recent advances in our understanding of the structure and function of deoxycytidine kinase (dCK), a critical enzyme required for the anti-tumor activity for many nucleoside analogs, have clarified the mechanistic role this kinase plays in chemo- and radio-sensitization. A heretofore unrecognized role of dCK in the DNA damage response and cell cycle machinery has helped explain the synergistic effect of these agents with radiotherapy. Since most currently employed nucleoside analogs are primarily activated by dCK, these findings lend fresh impetus to efforts focused on profiling and modulating dCK expression and activity in tumors. In this review we will briefly review the pharmacology and biochemistry of the major nucleoside analogs in clinical use that are activated by dCK. This will be followed by discussions of recent advances in our understanding of dCK activation via post-translational modifications in response to radiation and current strategies aimed at enhancing this activity in cancer cells.
- 15 September 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (18) , 4994-5002
Estrogen Receptor α Regulates ATM Expression through miRNAs in Breast Cancer
Purpose: Estrogen receptor α (ERα) is an essential element regulating mammary gland development and it contributes to breast cancer development and progression. Most of the ER-negative breast cancers display more aggressive clinical behaviors and are resistant to antiestrogen therapies. In addition, many ER-negative tumors show insensitivity to many chemotherapeutic drugs and radiotherapy, although mechanisms underlying this phenotype are less clear. Experimental Design: We conducted immunohistochemistry on 296 cases of breast cancer tissues using a variety of antibodies. On the basis of the clinical data, we conducted siRNA knockdown to study the role of ERα on ATM expression in breast cancer cell lines. Furthermore, we used antisense oligonucleotides against micro RNAs (miRNA) or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression. Finally we used in situ hybridization to assess miR-18a and -106a expression in breast cancer tissues. Results: We found that in ER-negative breast cancer tissues, expression of the ATM kinase, a critical DNA damage-response protein, is aberrantly upregulated. We also found that the locoregional recurrence rate after radiotherapy positively correlates with ATM expression. On the cellular level, we showed that ERα, but not ERβ, negatively regulates ATM expression. Furthermore, we identified that ERα activates miR-18a and -106a to downregulate ATM expression. We also showed that miR-18a and -106a were significantly underexpressed in ER-negative breast cancer tissues. Conclusions: We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer. Clin Cancer Res; 19(18); 4994–5002. ©2013 AACR.
- 15 September 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (18) , 4994-5002
Estrogen Receptor α Regulates ATM Expression through miRNAs in Breast Cancer
Purpose: Estrogen receptor α (ERα) is an essential element regulating mammary gland development and it contributes to breast cancer development and progression. Most of the ER-negative breast cancers display more aggressive clinical behaviors and are resistant to antiestrogen therapies. In addition, many ER-negative tumors show insensitivity to many chemotherapeutic drugs and radiotherapy, although mechanisms underlying this phenotype are less clear. Experimental Design: We conducted immunohistochemistry on 296 cases of breast cancer tissues using a variety of antibodies. On the basis of the clinical data, we conducted siRNA knockdown to study the role of ERα on ATM expression in breast cancer cell lines. Furthermore, we used antisense oligonucleotides against micro RNAs (miRNA) or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression. Finally we used in situ hybridization to assess miR-18a and -106a expression in breast cancer tissues. Results: We found that in ER-negative breast cancer tissues, expression of the ATM kinase, a critical DNA damage-response protein, is aberrantly upregulated. We also found that the locoregional recurrence rate after radiotherapy positively correlates with ATM expression. On the cellular level, we showed that ERα, but not ERβ, negatively regulates ATM expression. Furthermore, we identified that ERα activates miR-18a and -106a to downregulate ATM expression. We also showed that miR-18a and -106a were significantly underexpressed in ER-negative breast cancer tissues. Conclusions: We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer. Clin Cancer Res; 19(18); 4994–5002. ©2013 AACR.
- 1 April 2008
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 28 (8) , 2559-2566
A Novel ATM-Dependent Pathway Regulates Protein Phosphatase 1 in Response to DNA Damage
Protein phosphatase 1 (PP1), a major protein phosphatase important for a variety of cellular responses, is activated in response to ionizing irradiation (IR)-induced DNA damage. Here, we report that IR induces the rapid dissociation of PP1 from its regulatory subunit inhibitor-2 (I-2) and that the process requires ataxia-telangiectasia mutated (ATM), a protein kinase central to DNA damage responses. In response to IR, ATM phosphorylates I-2 on serine 43, leading to the dissociation of the PP1-I-2 complex and the activation of PP1. Furthermore, ATM-mediated I-2 phosphorylation results in the inhibition of the Aurora-B kinase, the down-regulation of histone H3 serine 10 phosphorylation, and the activation of the G2/M checkpoint. Collectively, the results of these studies demonstrate a novel pathway that links ATM, PP1, and I-2 in the cellular response to DNA damage.
- 1 April 2008
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 28 (8) , 2559-2566
A Novel ATM-Dependent Pathway Regulates Protein Phosphatase 1 in Response to DNA Damage
Protein phosphatase 1 (PP1), a major protein phosphatase important for a variety of cellular responses, is activated in response to ionizing irradiation (IR)-induced DNA damage. Here, we report that IR induces the rapid dissociation of PP1 from its regulatory subunit inhibitor-2 (I-2) and that the process requires ataxia-telangiectasia mutated (ATM), a protein kinase central to DNA damage responses. In response to IR, ATM phosphorylates I-2 on serine 43, leading to the dissociation of the PP1-I-2 complex and the activation of PP1. Furthermore, ATM-mediated I-2 phosphorylation results in the inhibition of the Aurora-B kinase, the down-regulation of histone H3 serine 10 phosphorylation, and the activation of the G2/M checkpoint. Collectively, the results of these studies demonstrate a novel pathway that links ATM, PP1, and I-2 in the cellular response to DNA damage.
- 27 July 2006
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 610 (1-2) , 14-20
ATR regulates hexavalent chromium-induced S-phase checkpoint through phosphorylation of SMC1
- 27 July 2006
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 610 (1-2) , 14-20
ATR regulates hexavalent chromium-induced S-phase checkpoint through phosphorylation of SMC1